Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; ErbB Receptors/antagonists & inhibitors; ErbB Receptors/genetics; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Mutation; Protein Kinase Inhibitors/therapeutic use; Quinazolines/therapeutic use; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Carboplatin/administration & dosage; Carcinoma, Non-Small-Cell Lung/enzymology; Carcinoma, Non-Small-Cell Lung/mortality; Carcinoma, Non-Small-Cell Lung/pathology; Chi-Square Distribution; Cisplatin/administration & dosage; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Europe; Exons; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms/enzymology; Lung Neoplasms/mortality; Lung Neoplasms/pathology; Male; Middle Aged; Molecular Targeted Therapy; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/adverse effects; Quinazolines/administration & dosage; Quinazolines/adverse effects; Taxoids/administration & dosage; Time Factors; Treatment Outcome; Gemcitabine